A next-generation TRK kinase inhibitor overcomes acquired resistance to prior trk kinase inhibition in patients with TRK fusion-positive solid tumors

Cancer Discovery

Volumn 7, Issue 9, 2017, Pages 963-972

  Drilon, Alexander ^a,b   Nagasubramanian, Ramamoorthy ^c   Blake, James F ^d   Ku, Nora ^e   Tuch, Brian B ^e   Ebata, Kevin ^e   Smith, Steve ^e   Lauriault, Veronique ^e   Kolakowski, Gabrielle R ^d   Brandhuber, Barbara J ^d   Larsen, Paul D ^d   Bouhana, Karyn S ^d   Winski, Shannon L ^d   Hamor, Robyn ^d   Wu, Wen I ^d   Parker, Andrew ^d   Morales, Tony H ^d   Sullivan, Francis X ^d   DeWolf, Walter E ^d   Wollenberg, Lance A ^d   Gordon, Paul R ^c   Douglas Lindsay, Dorothea N ^c   Scaltriti, Maurizio ^a   Benayed, Ryma ^a   Raj, Sandeep ^a   Hanusch, Bethany ^a   Schram, Alison M ^a   Jonsson, Philip ^a   Berger, Michael F ^a,b   Hechtman, Jaclyn F ^a,b   Taylor, Barry S ^a   Andrews, Steve ^d   Michael Rothenberg, S ^e   Hyman, David M ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEMOURS CHILDREN S HOSPITAL   (United States)

^d ARRAY BIOPHARMA INC   (United States)

^e Loxo Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; LAMIN; LAROTRECTINIB; PROTEIN TYROSINE KINASE A; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CELL PROLIFERATION; CHEMOTHERAPY; COLORECTAL CANCER; DISEASE DURATION; DRUG DOSE TITRATION; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; GROWTH INHIBITION; HYPERMETABOLISM; MOUSE; MUTATION; NEXT GENERATION SEQUENCING; NONHUMAN; SOLID MALIGNANT NEOPLASM; TUMOR GROWTH; WHOLE EXOME SEQUENCING; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NEOPLASM; NIH 3T3 CELL LINE; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; RECEPTOR, TRKA;

EID: 85028777325     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0507     Document Type: Article

References (22)

1. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5:25-34.
2. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-72.
3. Tognon C, Garnett M, Kenward E, Kay R, Morrison K, Sorensen PH. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and P13-kinase-Akt signaling for fibroblast transformation. Cancer Res 2001;61:8909-16.
4. Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M. Oncogenes in solid human tumours. Nature 1982;300:539-42.
5. The Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676-90.
6. Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers [abstract]. J Clin Oncol 35, 2017(suppl; abstr LBA2501).
7. Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov 2016;6:36-44.
8. Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mam-mary analogue secretory carcinoma (MASC). Ann Oncol 2016;27: 920-6.
9. Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013;368:2395-401.
10. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016;6:1118-33.
11. Drilon A, De Braud F, Siena S, Ou S-H, Patel M, Ahn M-J, et al. Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia, PA: AACR; 2016. Abstract nr. CT007.
12. Estrada-Bernal A, Le A, Tuch B, Kutateladze T, Doebele RC. TRK kinase domain mutations that induce resistance to pan-TRK inhibitor [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia, PA: AACR; 2015. Abstract no. C65.
13. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.
14. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629-40.
15. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97.
16. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5.
17. Arevalo JC, Conde B, Hempstead BL, Chao MV, Martin-Zanca D, Perez P. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol Cell Biol 2000;20: 5908-16.
18. Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, Pappo A. Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer 2016;63:1468-70.
19. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-88.
20. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
21. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra17.
22. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.